118
Views
19
CrossRef citations to date
0
Altmetric
Review

Regulatory issues for plant-made pharmaceuticals and vaccines

Pages 591-601 | Published online: 09 Jan 2014

References

  • Peterson RKD, Arntzen CJ. On risk and plant-based biopharmaceuticals. Trends Biotechnol. 22, 64–66 (2004).
  • Howard JA, Donnelly KC. A quantitative safety assessment model for transgenic protein products produced in agricultural crops. J. Agric. Environ. Ethics 17, 545–558 (2004).
  • Nakamura S, Takasaki H, Kobayashi K, Kato A. Hyperglycosylation of hen egg white lysozyme in yeast. J. Biol. Chem. 268, 12706–12712 (1993).
  • Ward PP, Chu H, Zhou X, Conneely OM. Expression and characterization of recombinant murine lactoferrin. Gene 204, 171–176 (1997).
  • Tomiya N, Narang S, Lee YC, Betenbaugh MJ. Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines. Glycoconj. J. 21, 343–360 (2004).
  • Brooks SA. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Mol. Biotechnol. 28, 241–255 (2004).
  • Hood EE, Woodard SL, Horn ME. Monoclonal antibody manufacturing in transgenic plants–myths and realities. Curr. Opin. Biotechnol. 13, 630–635 (2002).
  • Zhong G-Y, Peterson D, Delaney DE et al. Commercial production of aprotinin in transgenic maize seeds. Mol. Breed. 5, 345–356 (1999).
  • Woodard SL, Mayor JM, Bailey MR et al. Maize-derived bovine trypsin: characterization of the first large-scale, commercial protein product from transgenic plants. Biotechnol. Appl. Biochem. 37, 1–8 (2003).
  • Lamphear BJ, Streatfield SJ, Jilka JM et al. Delivery of subunit vaccines in maize seed. J. Control. Release 85, 169–180 (2002).
  • Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Med. 4, 607–609 (1998).
  • Kapusta J, Modelska A, Pniewski T et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 13, 1796–1799 (1999).
  • Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182, 302–305 (2000).
  • Yusibov V, Hooper DC, Spitsin SV et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20, 3155–3164 (2002).
  • Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 22, 4385–4389 (2004).
  • Thanavala Y, Mahoney M, Pal S et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl Acad. Sci. USA 102, 3378–3382 (2005).
  • Howard JA, Hood E. Bioindustrial and biopharmaceutical products produced in plants. Advances in Agronomy 85, 91–124 (2005).
  • Shah MM, Fujiyama K, Flynn CR, Joshi L. Sialylated endogenous glycoconjugates in plant cells. Nature Biotechnol. 21, 1470–1471 (2003).
  • Hood EE, Witcher DR, Maddock S et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol. Breed. 3, 291–306 (1997).
  • Rasmussen JR. Glycosylation of recombinant proteins. In: Biology of Carbohydrates. Ginsburg V, Robbins PW (Eds). JAI Press Ltd, Greenwich, CT, USA, 179–285 (1991).
  • van Ree R, Cabanes-Macheteau M, Akkerdaas J et al. β(1,2)-xylose and α(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens. J. Biol. Chem. 275, 11451–11458 (2000).
  • Chargelegue D, Vine ND, van Dolleweerd CJ, Drake PM, Ma JK. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 9, 187–194 (2000).
  • Wenderoth I, von Schaewen A. Isolation and characterization of plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences. Functional analyses in the Arabidopsis cgl mutant and in antisense plants. Plant Physiol. 123, 1097–1108 (2000).
  • Bakker H, Bardor M, Molthoff JW et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc. Natl Acad. Sci. USA 98, 2899–2904 (2001).
  • Streatfield SJ, Mayor JM, Barker DK et al. 2000 congress symposium on molecular farming: development of an edible subunit vaccine in corn against enterotoxigenic strains of Escherichia coli. Vitro Cell. Dev. Biol., Plant 38, 11–17 (2002).
  • Kusnadi AR, Nikolov ZL, Howard JA. Production of recombinant proteins in transgenic plants: practical considerations. Biotechnol. Bioeng. 56, 473–484 (1997).
  • Yuan Q, Hu W, Pestka JJ, He SY, Hart LP. Expression of a functional antizearalenone single-chain Fv antibody in transgenic Arabidopsis plants. Appl. Environ. Microbiol. 66, 3499–3505 (2000).
  • Menkhaus TJ, Bai Y, Zhang C, Nikolov ZL, Glatz CE. Considerations for the recovery of recombinant proteins from plants. Biotechnol. Prog. 20, 1001–1014 (2004).
  • Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 342, 76–78 (1989).
  • Huang Z, Elkin G, Maloney BJ et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 23, 1851–1858 (2005).
  • Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl Acad. Sci. USA 93, 5335–5340 (1996).
  • Borisjuk NV, Borisjuk LG, Logendra S, Petersen F, Gleba Y, Raskin I. Production of recombinant proteins in plant root exudates. Nat. Biotechnol. 17, 466–469 (1999).
  • Fischer R, Liao YC, Drossard J. Affinity purification of a TMV-specific recombinant full-size antibody from a transgenic tobacco suspension culture. J. Immunol. Methods 226, 1–10 (1999).
  • Torres E, Vaquero C, Nicholson L et al. Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies. Transgenic Res. 8, 441–449 (1999).
  • Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin. Emerg. Drugs 10, 185–218 (2005).
  • Daniell H, Khan MS, Allison L. Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci. 7, 84–91 (2002).
  • Vaquero C, Sack M, Chandler J et al. Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves. Proc. Natl Acad. Sci. USA 96, 11128–11133 (1999).
  • Dalsgaard K, Uttenthal A, Jones TD et al. Plant-derived vaccine protects target animals against a viral disease. Nature Biotechnol. 15, 248–252 (1997).
  • Streatfield SJ, Howard JA. Plant production systems for vaccines. Expert Rev. Vaccines 2, 763–775 (2003).
  • Kristinsson JB. Letter to the editor. Nature Biotechnol. 22, 508 (2004).
  • Bullerman LB. Occurrence of Fusarium and fumonisins on food grains and in foods. Adv. Exp. Med. Biol. 392, 27–38 (1996).
  • Padidam M. Chemically regulated gene expression in plants. Curr. Opin. Plant Biol. 6, 169–177 (2003).
  • Yang D, Guo F, Liu B, Huang N, Watkins SC. Expression and localization of human lysozyme in the endosperm of transgenic rice. Planta 216, 597–603 (2003).
  • Parmenter DL, Boothe JG, van Rooijen GJ, Yeung EC, Moloney MM. Production of biologically active hirudin in plant seeds using oleosin partitioning. Plant Mol. Biol. 29, 1167–1180 (1995).
  • Mariani C, Goldberg RB, Leemans J. Engineered male sterility in plants. Symp. Soc. Exp. Biol. 45, 271–279 (1991).
  • Zaitlin D, Chambers OD, Li B, Mundell RE, Davies HM. Letter to the editor. Nature Biotechnol. 22, 507 (2004).
  • Gleave AP, Mitra DS, Mudge SR, Morris BA. Selectable marker-free transgenic plants without sexual crossing: transient expression of cre recombinase and use of a conditional lethal dominant gene. Plant Mol. Biol. 40, 223–235 (1999).
  • Nikolov ZL, Woodard SL. Downstream processing of recombinant proteins from transgenic feedstock. Curr. Opin. Biotechnol. 15, 479–486 (2004).

Websites

  • Fernandez M, Crawford L, Hefferan C. Pharming the field: a look at the benefits and risks of bioengineering plants to produce pharmaceuticals. Proceedings from a workshop sponsored by the Pew Initiative on Food and Biotechnology, the US Food and Drug Administration and the Co-operative State Research, Education and Extension Service of the US Department of Agriculture (2002) http://pewagbiotech.org/events/0717/ConferenceReport.pdf (Accessed July 2005)
  • Food industry comments on proposed FDA regulations for plant-made pharmaceuticals (2005) www.gmabrands.com/publicpolicy/docs/Comment.cfm?docid=1068 (Accessed July 2005)
  • Guidance for industry: drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals (2002). www.fda.gov/cber/gdlns/bioplant.pdf (Accessed July 2005)
  • Dry LJ. The case for plant-made pharmaceuticals. Bio News (2002) www.bio.org/healthcare/pmp/BIONews200204.pdf (Accessed July 2005)
  • A brief primer on manufacturing therapeutic proteins. Biotechnology Industry Organization (2005) www.bio.org/healthcare/pmp/ factsheet1.asp (Accessed July 2005)
  • Alpha interferon: the first Biolex protein www.biolex.com/alfa.html (Accessed July 2005)
  • Meristem Therapeutics www.meristem-therapeutics.com (Accessed July 2005)
  • Ventria Bioscience www.ventriabio.com/products/ lysozome.asp (Accessed July 2005)
  • Planet Biotechnology www.planetbiotechnology.com/ products.html (Accessed July 2005)
  • ProdiGene www.prodigene.com (Accessed July 2005)
  • Large Scale Biology www.lsbc.com/biomanufacturing.html (Accessed July 2005)
  • Updated guidance on bioengineered plants for producing pharmaceuticals or industrial products for applicants developing these plants for release. United States Department of Agriculture (2004) www.aphis.usda.gov/brs/pdf/011404.pdf (Accessed July 2005)
  • Reference document for confinement and development of plant-made pharmaceuticals in the United States. Biotechnology Industry Organization (2002) www.bio.org/healthcare/pmp/PMPConfinementPaper.pdf (Accessed July 2005)
  • What are the key components of BRS’ Compliance and Enforcement Program? Biotechnology Regulatory Services (2005) www.aphis.usda.gov/brs/compliance3.html (Accessed July 2005)
  • Field testing of plants engineered to produce pharmaceutical and industrial compounds. Department of Agriculture, Animal and Plant Health Inspection Service, Federal Register 68(46), 11337–11340 (2003) www.aphis.usda.gov/brs/pdf/7cfr.pdf (Accessed July 2005)
  • Glyphosate; pesticide tolerance. United States Environmental Protection Agency, Federal Register 70(31), 7861–7864 (2005). www.epa.gov/fedrgstr/EPA-PEST/2005/February/Day-16/p2983.htm (AccessedJuly 2005)
  • Plant-Made Pharmaceuticals: Frequently Asked Questions. Biotechnology Industry Organization www.bio.org/healthcare/pmp/factsheet2.asp?p=yes& (Accessed July 2005)

Patents

  • Rodriguez RL. Process for protein production in plants. US 5889189 (1999).
  • Oliver MJ, Quisenberry JE, Trolinder NLG, Keim DL. Control of plant gene expression. US 5723765 (1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.